Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  MacLeod, Iain J ^a,b   Rowley, Christopher F ^a,b,c   Lockman, Shahin ^a,b,d   Ogwu, Anthony ^b   Moyo, Sikhulile ^b   Van Widenfelt, Erik ^b   Mmalane, Mompati ^b   Makhema, Joseph ^b   Essex, M ^a,b   Shapiro, Roger L ^a,b,c  

^a Harvard AIDS Institute   (United States)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Abacavir; AIDS; Antiretroviral; Cytokine; HIV; Inflammation; Transcription

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; C REACTIVE PROTEIN; CD40 LIGAND; INTERLEUKIN 6; INTERLEUKIN 8; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LYMPHOTOXIN; RANTES; VIRUS RNA; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOKINE; IMMUNOLOGIC FACTOR;

ADULT; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; ARTICLE; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GENETIC TRANSCRIPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; METHODOLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYTOKINES; DIDEOXYNUCLEOSIDES; FEMALE; HIV; HUMANS; IMMUNOLOGIC FACTORS; TRANSCRIPTION, GENETIC; VIRAL LOAD;

EID: 84867464224     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17393     Document Type: Conference Paper

References (33)

1. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-30.
2. SfMoA-RTIDS Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17-24.
3. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228-38.
4. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20-8.
5. Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52:929-40.
6. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993-2004.
7. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of myocardial infarction with ABC use: an FDA meta-analysis (Paper # 808). Conference on Retroviruses and Opportunistics Infections; Boston; 2011.
8. Satchell CS, O'Halloran JA, Cotter AG, Peace AJ, O'Connor EF, Tedesco AF, et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavircontaining antiretroviral therapy. J Infect Dis. 2011;204:1202-10.
9. Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011;25:2243-8.
10. De Pablo C, Orden S, Apostolova N, Blanquer A, Esplugues JV, Alvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. AIDS. 2010;24:1259-66.
11. Hammond E, McKinnon E, Mallal S, Nolan D. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS. 2008;22:2540-3.
12. Martinez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca M, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 2010;24:F1-9.
13. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis. 2011;11:40.
14. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362:2282-94.
15. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 2001;29:e45.
16. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003;19: 368-75. (Pubitemid 36284936)
17. Li WS, Kwan YW, Leung GPH. Possible mechanisms underlying abacavirrelated cardiovascular complications. Cardiovasc Res. 2010;87:S56.
18. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54:669-77.
19. Naoum JJ, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lymphotoxin-alpha and cardiovascular disease: clinical association and pathogenic mechanisms. Med Sci Monit. 2006;12:RA121-4. (Pubitemid 44031649)
20. Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol. 2007;27:929-35. (Pubitemid 46606727)
21. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol. 2006;26:194-9. (Pubitemid 43732249)
22. Glenister KM, Sparrow RL. Level of platelet-derived cytokines in leukoreduced red blood cells is influenced by the processing method and type of leukoreduction filter. Transfusion. 2010;50:185-9.
23. Gallo RC, Garzino-Demo A, DeVico AL. HIV infection and pathogenesis: what about chemokines? J Clin Immunol. 1999;19:293-9. (Pubitemid 29489394)
24. Boger CA, Fischereder M, Deinzer M, Aslanidis C, Schmitz G, Stubanus M, et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis. 2005;183: 121-9. (Pubitemid 41416830)
25. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004;25:1438-46. (Pubitemid 39078251)
26. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, et al. CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2007; 27:373-9. (Pubitemid 46143054)
27. Groer MW, Davis MW, Smith K, Casey K, Kramer V, Bukovsky E. Immunity, inflammation and infection in post-partum breast and formula feeders. Am J Reprod Immunol. 2005;54:222-31. (Pubitemid 41309280)
28. Worm MM, Tsytsykova A, Geha RS. CD40 ligation and IL-4 use different mechanisms of transcriptional activation of the human lymphotoxin alpha promoter in B cells. Eur J Immunol. 1998;28:901-6. (Pubitemid 28116203)
29. Moriuchi H, Moriuchi M, Fauci AS. Nuclear factor-kappa B potently upregulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol. 1997;158:3483-91. (Pubitemid 127484070)
30. Srahna M, Remacle JE, Annamalai K, Pype S, Huylebroeck D, Boogaerts MA, et al. NF-kappaB is involved in the regulation of CD154 (CD40 ligand) expression in primary human T cells. Clin Exp Immunol. 2001;125:229-36. (Pubitemid 32758433)
31. Kunsch C, Rosen CA. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol. 1993;13:6137-46. (Pubitemid 23292608)
32. Wood JN. Regulation of NF-kappa B activity in rat dorsal root ganglia and PC12 cells by tumour necrosis factor and nerve growth factor. Neurosci Lett. 1995;192:41-4.
33. MacLeod IJ, Shapiro RL, Lockman S, Ogwu A, Rowley CF, Moyo S, et al. Differential expression of inflammatory cytokine mRNA transcripts in women on an ABC-containing regimen for the prevention of MTCT (Paper # 816). Conference on Retroviruses and Opportunistics Infections; Boston; 2011.